J&J's Halda-born RIPTAC hits 75% response in late-line prostate cancer
- J&J's oral RIPTAC JNJ-6143, inherited with its roughly $3 billion Halda purchase, posted a 75% confirmed response rate (12 of 16 measurable-disease patients) in Phase 1 data at ESMO.
- Patients had heavily pretreated metastatic castration-resistant prostate cancer, with a median of four prior therapies.
- A 50 mg daily dose was chosen, with nausea and raised lipids most common; Phase 2 is planned.
💡 Points
Twelve responders out of sixteen is a striking line, but it is a small, early Phase 1 cut. The more useful point is for J&J's roughly $3 billion Halda purchase: a 75% response in patients with a median of four prior therapies makes Phase 2 the real test of whether this oral RIPTAC can anchor a prostate franchise.
ESMO 2026: J&J delivers ‘immaculate’ early data for prostate cancer drug from Halda ↗